A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Intra-articular Dose of the TrkA Inhibitor, GZ389988A, in Patients with Painful Osteoarthritis of the Knee
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs GZ 389988 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Sanofi; Sanofi Genzyme
- 26 Oct 2017 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 Planned End Date changed from 1 Sep 2017 to 29 Sep 2017.
- 28 Aug 2017 Planned End Date changed from 1 Sep 2017 to 29 Sep 2017.